Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
News|Articles|May 1, 2012

Applied Clinical Trials

  • Applied Clinical Trials-05-01-2012
  • Volume 21
  • Issue 5

A Financial Case for Loyalty Management

ISR Reports

It sounds fairly intuitive that if a service provider consistently meets customer expectations, then it will prosper financially. Industry Standard Research examined this relationship using four years of service provider performance data paired with share price for five leading CROs. The conclusion: There exists a very strong relationship between a CRO's service quality, as measured by ISR's Service Variability Index (SVI™), and its financial performance as measured by share price. Readers will recall that ISR created the SVI in 2009 as a representation of a service provider's consistency in meeting customer expectations.

On average service providers have improved their delivery consistency over the past four years.

ISR analyzed the SVI data from 2009, 2010, 2011, and 2012 alongside each company's closing stock price on the first day of trading in that year. This analysis includes 816 sponsor ratings of encounters with Covance, ICON, Kendle (to 2011), PAREXEL, and PPD. Both the SVI and the share price were indexed (100), using 2009 as the base year.

Two conclusions of note: Overall, these service providers have, on average, improved their delivery consistency over the past four years and with an R2 value of 70%, the SVI has a very strong relationship to the average company share price.

—Industry Standard Research, www.ISRreports.com.

Articles in this issue


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.